Tag
This review synthesizes evidence comparing brain atrophy patterns in MS, MOGAD, and AQP4+ NMOSD, highlighting MOGAD’s atrophy association with inflammatory activity and lesion dynamics, emphasizing distinct pathogenic mechanisms and c
This study reveals that midlife plasma p-tau181 predicts faster memory decline over 11 years, highlighting a long prodromal phase of Alzheimer’s disease. Late-life biomarkers p-tau181, NfL, and GFAP correlate with accelerated cognitive decl
Liver transplantation facilitates early neurocognitive recovery in end-stage liver disease patients by restoring cortical network activities, with S-methyl-5′-thioadenosine playing a pivotal neuroprotective role through modulating neu
A large-scale multicenter study reveals that persistent high-level Epstein-Barr nuclear antigen 1 (EBNA-1) peptide antibody titers serve as a highly specific biomarker, effectively distinguishing Multiple Sclerosis from other neuroinflammat
**Refining Content Structure** I’m now deeply immersed in the content. I’ve drafted the introduction, designed to capture attention and set the scene. I am expanding on the key findings, including correlations, and the clinical
A Phase 1 trial published in NEJM Evidence demonstrates that allogeneic, umbilical cord-derived regulatory T cells are safe and potentially effective in slowing the progression of ALS, providing a scalable, off-the-shelf alternative to trad
The AZA-PD phase 2 trial found that while azathioprine was well-tolerated in early Parkinson’s disease, it did not significantly improve gait-axial scores. However, exploratory data suggests potential motor benefits in female patients
The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark
A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–mo
Higher adherence to an anti-inflammatory diet is linked to lower all-cause mortality and a trend toward reduced Alzheimer’s disease mortality, particularly among men and non-Hispanic Whites, highlighting dietary modification as a pote
